^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

AGK-BRAF fusion

i
Other names: AGK, Acylglycerol Kinase, Multiple Substrate Lipid Kinase, Acylglycerol Kinase, Mitochondrial, Multi-Substrate Lipid Kinase, HsMuLK, MULK, HAGK, MTDPS10, CATC5, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa
Entrez ID:
2ms
Journal
|
BRAF (B-raf proto-oncogene) • AGK (Acylglycerol Kinase)
|
AGK-BRAF fusion
6ms
Plasma-Based Genotyping For Monitoring Patients With Thyroid Cancer (ATA 2023)
Although the methodology is still evolving, our findings suggest that this non‐invasive approach can be incorporated into the routine management of patients with malignant thyroid neoplasm as it may help the early detection of therapeutically targetable mutations. We emphasize that liquid biopsy test can be repeated through the follow‐up to complement existing tests with low cost and convenience for the patient. We also anticipate that that this blood test may help early detection of thyroid tumors.
Clinical
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • STRN (Striatin) • RAS (Rat Sarcoma Virus) • AGK (Acylglycerol Kinase) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
|
BRAF V600E • BRAF V600 • BRAF fusion • AGK-BRAF fusion • STRN-ALK fusion
11ms
Clinical Activity of the Type II Pan-RAF Inhibitor Tovorafenib in BRAF-Fusion Melanoma (EADO 2023)
Previous therapy with pembrolizumab provided a best response of stable disease (SD) after 11 weeks of therapy...Patient 2 is a 35-year-old white male with a TRIM33-BRAF fusion malignant melanoma, and progressed after treatment with radiation, nivolumab, and nivolumab + ipilimumab... Early results from the first three patients of this ongoing trial showed tovorafenib is generally well tolerated and has encouraging antitumor activity in BRAF-fusion melanoma.
Clinical • PD(L)-1 Biomarker
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TRIM33 (Tripartite Motif Containing 33) • AGK (Acylglycerol Kinase)
|
BRAF mutation • NRAS mutation • BRAF fusion • AGK-BRAF fusion • NRAS mutation + BRAF mutation • RAF1 amplification
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • tovorafenib (DAY101)
1year
Rapid tissue donation identifies LAG3 as a potential therapeutic target for ALK fusion positive lung cancer (AACR 2023)
Analysis of two tissue microarrays comprised of 130 tumor cores from multiple tissue sites of the first 10 NSCLC RTD donors revealed that 66% of tumor cores had >1% LAG3 expression in CD3+ T cells. Among the three patients with ALK fusion-positive NSCLC, 83% (5 of 6 cores), 85% (6 of 7 cores), and 100% (18 of 18 cores) of the tissue cores had >1% LAG3 expression in T cells. The median LAG3 expression in T cells measured by mIF was 1.8% in 99 tumor cores from the ALK fusion-negative study cohort versus 7.3% in the 31 cores from the ALK fusion-positive subset (p=0.004).
PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • LAG3 (Lymphocyte Activating 3) • AGK (Acylglycerol Kinase)
|
PD-L1 expression • BRAF mutation • ALK positive • ALK fusion • BRAF fusion • LAG3 expression • AGK-BRAF fusion • ALK L1196M
over1year
Post-Therapy Samples Collected through Rapid Tissue Donation Confirms the Necessity of Tissue-Based NextGeneration Sequencing in Identifying Driver Mutations (AMP 2022)
These patients received various therapies including pembrolizumab, nivolumab, capmatinib, bevacizumab, osimertinib, brigatinib, erlotinib, and alectinib, as well as sotorasib. Collection and sequencing of RTD samples provides an opportunity to detect resistance mutations and to understand more about post-treatment disease progression and tumor heterogeneity. The identification of drivers by comprehensive NGS tissue testing in two cases serves as a reminder about the value of such testing when no drivers are identified by small panels or blood-based NGS testing.
Next-generation sequencing • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • EML4 (EMAP Like 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • AGK (Acylglycerol Kinase)
|
KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • EGFR exon 20 insertion • KRAS G12V • MET exon 14 mutation • EML4-ALK fusion • ALK fusion • MET mutation • KRAS G12 • NRAS Q61 • BRAF fusion • EGFR exon 20 mutation • AGK-BRAF fusion • NRAS Q61L • EGFR mutation + PIK3CA mutation • KRAS Q61L
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tagrisso (osimertinib) • erlotinib • Alecensa (alectinib) • Lumakras (sotorasib) • Alunbrig (brigatinib) • Tabrecta (capmatinib)
almost3years
Genomic Profile of Columnar Cell Variant of Papillary Thyroid Carcinoma. (PubMed, Histopathology)
We found that CCV is primarily a BRAF-driven tumor, with most also harboring secondary oncogenic mutations and multiple chromosomal gains and losses. Moreover, our findings suggest that molecular analysis could potentially help risk stratify CCV.
Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • AGK (Acylglycerol Kinase)
|
TP53 mutation • BRAF V600E • BRAF V600 • AGK-BRAF fusion • TERT mutation • TERT promoter mutation
3years
[VIRTUAL] Alterations in nuclear DNA organization in sporadic pediatric Papillary Thyroid Carcinoma (PTC) (AACR 2021)
Moreover, can also observe a trend to a more disrupted chromatin organization in AGK-BRAF tumors and tumors from <10 y.o. patients, which can be associated with the aggressiveness of the disease in these cases. Further analysis are needed to better understand wether AGK-BRAF fusion is associated with poor prognosis in pediatric PTC and if it could be related to a high genomic instability caused by this fusion.
Clinical
|
BRAF (B-raf proto-oncogene) • AGK (Acylglycerol Kinase)
|
BRAF fusion • AGK-BRAF fusion
almost4years
[VIRTUAL] Three-dimensional (3D) telomere signatures of sporadic pediatric papillary thyroid carcinoma (PTC) (AACR-II 2020)
The 3D nuclear telomere signature was able to detect differences in telomere architecture in tumours, compared to normal. Further analysis is necessary to define whether nuclear telomere architecture and specific genetic alterations observed in pediatric thyroid cancer are associated.
Clinical
|
BRAF (B-raf proto-oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • AGK (Acylglycerol Kinase)
|
BRAF V600E • BRAF V600 • AGK-BRAF fusion